The case for & against
Bull & Bear analysis
Phathom Pharmaceuticals (NASDAQ: PHAT) is a clinical-stage biopharmaceutical company that focuses on developing therapies for gastrointestinal diseases, with a particular emphasis on the treatment of gastroesophageal reflux disease (GERD). The company has positioned itself within the rapidly growing GI treatment segment, prominently featuring its flagship product, VOQUEZNA® (vonoprazan), which has received FDA approval to treat both non-erosive and erosive GERD in adults, as well as for *Helicobacter pylori* eradication in combination with antibiotics. The firm is part of a critical therapeutic market where effective treatments can address significant unmet patient needs.
Bull says
- ↑Q1 revenue rose 104% YoY to $58.3M, driven by Voquezna adoption
- ↑Voquezna fills surged 115% YoY to 1.35M, capturing 45% market share
- ↑Operating expenses fell 43% YoY to $56.2M, boosting cost discipline
- ↑Sales force grew by ~50 reps to >290, expanding gastroenterologist reach
- ↑Barclays upgrade to overweight and $18 PT reflect analyst confidence
- ↑High growth factor and strong balance‐sheet quality underpin momentum
Bear says
- ↓Q1 loss of $9.9M and negative earnings yield hamper margin expansion
- ↓Auditor going‐concern warning and tight cash runway threaten viability
- ↓Altman Z-Score and leverage risk suggest potential financial distress
- ↓Emerging PCAB competitors may erode Voquezna’s market share
- ↓2026 revenue guidance of $320–345M may already be priced in
- ↓Negative profitability factor and high volatility risk undermine valuation
Investment themes with PHAT
Drug development driving global healthcare solutions
Earnings Call · Q1 2026 · Mgmt. Guidance
Transcript signals
Bull points
- We more than doubled revenue from Q1, 2025 to Q1, 2026. We believe we're on track to potentially achieving 1 billion in annual revenue from gastroenterology prescriptions with the potential for a second billion from primary care prescriptions as patients cycle back to share their Viquezna experience with their PCP and we evolve our sales and marketing focus to include this segment in the future.
- In Q1 of this year, we expanded our sales team with nearly 50 new sales representatives trained and deployed into the field in recent months. Our Salesforce alignment to enable high-frequency calls on gastroenterologists is complete. We have more than 290 reps in place to start Q2.
- We believe new-to-brand conversions drive future TRX growth as we expect that many of these patients who are converted to Bequesna will elect to remain on Bequesna.
Bear points
- Q1, 2026 revenue was somewhat light compared to our internal expectation due to market access, seasonality, and other factors like winter storm and deployment timing of new Salesforce team members.
- We reported a loss from operation excluding stock-based compensation of approximately $9.9 million.
- Our Q1, 2026 revenue was somewhat light compared to our internal expectation due to market access, seasonality, and other factors like winter storm and deployment timing of new Salesforce team members.